Sana Biotechnology, Inc.

This biotechnology company develops ex vivo and in vivo cell engineering platforms to create therapies for severe medical conditions. Its research focuses on treatments for type 1 diabetes, B-cell malignancies, and autoimmune disorders. The firm's primary product candidates include SC451, an engineered stem cell-derived pancreatic islet cell therapy designed to restore normal glucose levels without immunosuppression, and SG293, an in vivo CAR T therapy delivered via fusosomes to deplete disease-causing B cells. These therapeutic candidates target patients diagnosed with insulin-dependent diabetes, hematologic cancers, and B-cell-driven autoimmune diseases.

The company maintains worldwide commercial rights to its pipeline and utilizes external contract development and manufacturing organizations alongside an internal master cell bank. Clinical evaluation includes an investigator-sponsored trial at Uppsala University Hospital, and regulatory discussions span multiple international jurisdictions. The excerpt does not disclose the company's headquarters location or specific facility figures.

Summary of the business section of Sana Biotechnology's latest annual report, written by StockData.

“As of December 31, 2025, we had 142 employees, 104 of whom were primarily engaged in research and development activities.”